Siltuximab

Source: Wikipedia, the free encyclopedia.
Siltuximab
IL-6
Clinical data
Trade namesSylvant
Other namesCNTO 328
License data
ATC code
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6450H9932N1688O2016S50
Molar mass144983.21 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Siltuximab (

Castleman's disease.[8][9]

On April 23, 2014, siltuximab was FDA approved under the brand name of Sylvant

Medical uses

Used for the treatment of idiopathic multicentric Castleman disease (iMCD).[13]

Clinical trials

Siltuximab has demonstrated significant efficacy and safety in patients with idiopathic multicentric

response rates.[18]

Side effects

Siltuximab may lower resistance to infections and should not be administered to patients with severe infections. Siltuximab should be discontinued in patients with severe infusion related reactions, anaphylaxis, severe allergic reactions or cytokine release syndromes. Live vaccines should not be administered to patients receiving siltuximab since IL-6 inhibition may interfere with normal immune response to new antigens.[13]

Common The following has been shown to occur in treatment of Multicentric

Castleman's disease with siltuximab during a clinical trial (>10% compared to placebo):[13]

Long term exposure

Drug interactions

Siltuximab may increase

CYP450 substrates. Co-administration of siltuximab and CYP450 substrates with narrow therapeutic index such as warfarin, ciclosporin or theophylline should be closely monitored.[13]

Mechanism of action

Siltuximab is a chimeric

VEGF) and autoimmune phenomena.[13]

References

  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  3. ^ "Siltuximab mechanism of action". HemOnc.org - A Free Hematology/Oncology Reference.
  4. PMID 26854213
    .
  5. .
  6. .
  7. ^ "Siltuximab". ClinicalTrials.gov.
  8. PMID 20625121
    .
  9. .
  10. ^ "Sylvant official website".
  11. ^ "Siltuximab approval". Food and Drug Administration. 23 April 2014. Archived from the original on 3 June 2014.
  12. ^ "Castleman disease: Siltuximab cancer regimen & references". HemOnc.org - A Free Hematology/Oncology Reference.
  13. ^ a b c d e "Sylvant Prescribing Information" (PDF). janssenmd. Retrieved 3 November 2014.
  14. PMID 26634298
    .
  15. .
  16. .
  17. .
  18. .